Navigation Links
Clinical Outcomes of Nonsmall Cell Lung Cancer Patients can Be Classified by New Algorithms

Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall-cell lung cancer (NSCLC) using mass spectrometry techniques . Currently, clinicians do not have adequate methods for determining which patients will benefit from treatment with certain drugs. The new models could help physicians decide who will benefit from certain treatment options.

The studies are published in the June 6 Journal of the National Cancer Institute. In one study, an international team led by David Carbone, M.D., Ph.D., of the Vanderbilt-Ingram Cancer Center in Nashville, developed an algorithm to predict the outcomes of NSCLC patients treated with the drugs gefitinib and erlotinib, two tyrosine kinase inhibitors. The algorithm places patients into categories indicating good or poor survival before treatment with one of the drugs and is based on the pattern of a group of proteins in the patients blood serum.

The authors developed the algorithm on a group of patients with known outcomes then tested it on pretreatment serum for independent validation and control groups. Patients who were predicted to have good outcomes survived for a median of 306 days, while those in the poor group survived a median of 107 days.

In the clinical development of biomarkers for the individualization of therapy, it is important to distinguish between those who will benefit from an intervention from those independent of the planned intervention. Biomarkers predictive for survival benefit from an intervention are much more useful for guiding managementthe authors said.Use of (Protein)signature will reduce rates of both overtreatment and undertreatment and improve survival for NSCLC patients, the authors added.

In the second study, Kiyoshi Yanagisawa, M.D., Ph.D., of Nagoya University in Japan, and colleagues analyzed protein patterns in NSCLC tumor tissue and normal lung tissue. The researchers identified a pattern th at was associated with increased survival among NSCLC patients and may distinguish patients with poor prognosis from those with good prognosis. They also tested their model on independent validation and control groups.


Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
8. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Cancer Clinical Research in India
11. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
Post Your Comments:

(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology: